Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients ...

WILMINGTON, Mass. — WILMINGTON, Mass. — Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $69.7 million. On a per-share basis, the Wilmington, ...

Charles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating ...

New heat pump technology under construction will pull energy out of the river and convert it to steam for heating industrial ...

Charles River Labs (CRL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tejas Savant from Morgan Stanley maintained a Hold rating on the ...

UBS raised the firm’s price target on Charles River (CRL) to $250 from $240 and keeps a Buy rating on the shares post the earnings ...

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion ...

NJ Bio and Charles River Announce a Strategic Alliance to Advance ADC Development and Manufacturing Services ...

Shipments of research monkeys by Charles River Laboratories, one of the largest U.S. clinical research organizations, have ...